Allison Wright Willis, MD
Neurology · Philadelphia, PANPI 1851591721
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $50,164 with a category attached, or 99.7%. Acadia Pharmaceuticals Inc accounts for 99.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2020 at $50,000 and has fallen 99.7% since, to $152 in 2024. Among neurology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4 payments — averaging $12,541 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$50K
- Eisai Inc.$125
- AbbVie$27
- GSK$11
Across 3 payments — averaging $70,980 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$213K
What the payments were for
- Grants$50,000100%
- Food & beverage$1640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 1 | $50,000 |
| Eisai Inc. | 1 | $125 |
| AbbVie | 1 | $27 |
| GSK | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$50,164 in reported general payments places this provider in the 90th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $144,702 |
| GocovriAmantadine Hcl | 11 | $17,937 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 21 | $8,485 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 122 | $5,768 |
| Carbidopa | 12 | $3,873 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 41 | $3,451 |
| AmantadineAmantadine Hcl | 25 | $2,993 |
| RivastigmineRivastigmine Tartrate | 12 | $975 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $782 |
| Clonazepam | 27 | $252 |
| Bupropion XlBupropion Hcl | 11 | $237 |
Paid to pharmacies, not to this prescriber.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Joseph BergerPhiladelphia$384K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.